What is the Casi Pharmaceuticals Inc. stock price forecast?

Casi Pharmaceuticals Inc. is currently trading at $0.15. View real-time AI analysis on Alpha Lenz.

What is Casi Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Casi Pharmaceuticals Inc. on Alpha Lenz.

What is Casi Pharmaceuticals Inc.'s P/E ratio?

Casi Pharmaceuticals Inc.'s P/E ratio is -0.1.

Casi Pharmaceuticals Inc.

NASDAQ · CASI

$0.15-0.02(-12.43%)Pre-market

Ask about Casi Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Casi Pharmaceuticals Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -301.8%.”

Ask for details →

Company Overview

Casi Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics in the treatment of various types of cancer. The company's primary aim is to address the unmet clinical needs within the oncology sector, bringing advanced and effective treatment options to patients globally. Casi Pharmaceuticals Inc. leverages its strategic partnerships and distribution networks primarily across the North American and Asian markets, facilitating the development and delivery of their therapies. The company engages in late-stage clinical trials and regulatory approvals, with a focus on expanding its product pipeline through both in-house developments and strategic acquisitions. With a commitment to enhancing therapeutic efficacy and patient outcomes, Casi Pharmaceuticals Inc. plays a significant role in pioneering cancer treatment solutions, contributing to advancements in the healthcare and life sciences industries.

CEOMr. David A. Cory M.B.A., R.Ph.

Websitehttps://www.casipharmaceuticals.com

SectorHealthcare

IndustryBiotechnology

Employees233

Company Statistics

FY 2024

Profile

$2.30MMarket Cap

$28.54MRevenue

0.00Shares Out

233Employees

Margins

39.06%Gross

-126.69%EBITDA

-137.41%Operating

-133.40%Pre-Tax

-137.57%Net

Valuation

-0.06P/E

1.24P/B

0.08EV/Sales

-0.30EV/EBITDA

-0.08P/FCF

Growth (CAGR)

-1.84%Rev 3Yr

47.19%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-60.99%ROA

-301.80%ROE

-57.70%ROIC

Financial Health

$13.47MCash & Cash Equivalents

$38.35MNet Debt

2799.73%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Casi Pharmaceuticals Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -301.8%.”

Ask for details →

Frequently Asked Questions

Casi Pharmaceuticals Inc. (ticker: CASI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 233 employees. Market cap is $2M.

The current price is $0.15 with a P/E ratio of -0.06x and P/B of 1.24x.

ROE is -301.80% and operating margin is -137.41%. Annual revenue is $29M.